Stock Detail
BIODELIVERY SCIENCES INTERNATIONAL INC
Sector: Biotechnology
Latest Quote @ Tue May 5 19:13:14 (15 min delayed)
| $4.26 |
$5.65 |
$4.34 |
-0.19 |
-4.19% |
|
Last Day's Data
| $4.53 |
$4.72 |
$0.00 |
0.00% |
0.00 |
$4.74 |
| $4.67 |
$4.50 |
473,438.00 |
178.26M |
177,244.00 |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 4.80 |
4.66 |
4.58 |
4.44 |
4.36 |
Stock Profile
BioDelivery Sciences International, Inc. operates as a specialty biopharmaceutical company that uses its licensed and patented drug delivery technologies to develop and commercialize new formulations of proven therapeutics targeted at acute treatment opportunities, such as pain, anxiety, nausea and vomiting, and infections. Its lead product under development is Emezine, which is used for treating nausea and vomiting, is in pre-registration stage. The company's licensed drug delivery technologies include the Bioral nanocochleate drug delivery technology, which is designed for a range of applications; and the BEMA drug delivery disc technology, which is applied to the inner cheek membrane. Its Bioral Amphotericin B is an anti-fungal treatment for treating systemic fungal infections. The company's lead BEMA product under development is BEMA Fentanyl, a treatment for cancer pain. BioDelivery Sciences is also developing BEMAT Long Acting Analgesic for treating pain conditions, including post operative and chronic pain due to osteoarthritis, lower back disorders, and rheumatoid arthritis. In addition, the company has a clinical development and license agreement with Clinical Development Capital, LLC relating to its BEMA Fentanyl product. BioDelivery Sciences was incorporated in 1997 and is headquartered in Morrisville, North Carolina.
